CBD Improved Dystonia Symptoms by 20-50% but Worsened Parkinson's Features | Research

The takeaway

Five patients with dystonic movement disorders showed 20-50% improvement with oral CBD at doses up to 600 mg/day, but two patients with coexisting Parkinson's features experienced worsened tremor and slowed movement.

Read this if you are interested in CBD's effects on movement disorders and want to understand both its potential benefits and risks.

20-50% improvement in dystonia across all five patients

What the researchers found

In this preliminary open-label study, five patients with dystonic movement disorders received oral CBD at escalating doses from 100 to 600 mg per day over six weeks, alongside their standard medications.

All five patients showed dose-related improvement in their dystonia, ranging from 20% to 50%. Side effects were mild: low blood pressure, dry mouth, psychomotor slowing, lightheadedness, and sedation.

However, a notable adverse finding emerged. Two patients who had Parkinson's features alongside their dystonia experienced worsened hypokinesia (slowed movement) and resting tremor at doses above 300 mg/day. This suggested CBD has both antidystonic and Parkinsonism-aggravating effects, a dual action with significant clinical implications.

Why it matters

This was one of the earliest clinical studies of CBD for a neurological movement disorder. The finding that CBD helped dystonia but worsened Parkinsonism highlighted that cannabinoid effects on movement are complex and condition-specific, not uniformly beneficial.

The numbers in context

Five patients. CBD doses: 100 to 600 mg/day over 6 weeks. Improvement range: 20-50% in dystonia. Parkinsonism worsened in 2 of 5 patients at doses above 300 mg/day.

How the study worked

Open-label pilot study with five dystonia patients. Oral CBD was escalated from 100 to 600 mg/day over 6 weeks alongside existing medications. No placebo control or blinding.

What this study cannot tell us

Open-label design with no placebo control means improvement could reflect placebo effects or natural variation. Only five patients. CBD was added to existing medications, making it difficult to isolate its specific contribution.

How to read the evidence

An open-label pilot study without placebo control. Provides preliminary signal but cannot establish efficacy.

When this study was published

Published in 1986. CBD research has expanded substantially, though large-scale trials for movement disorders remain limited.

The bigger picture

This study opened the door to CBD research in movement disorders while simultaneously raising caution flags. The contrast between dystonia improvement and Parkinson's worsening demonstrated that CBD's effects on motor circuits are nuanced and cannot be assumed to be universally positive for all movement conditions.

Questions still open

What mechanism explains CBD's opposing effects on dystonia versus Parkinsonism? Would lower CBD doses help dystonia without worsening Parkinson's features? Can these findings be replicated in a controlled trial?

Common questions

Did CBD help with movement disorders?

It improved dystonia symptoms by 20-50% in all five patients, but worsened Parkinson's features in two patients at doses above 300 mg/day.

What were the side effects?

Mild: low blood pressure, dry mouth, psychomotor slowing, lightheadedness, and sedation. The more concerning effect was worsening of Parkinsonism in susceptible patients.

Read the original research

Open label evaluation of cannabidiol in dystonic movement disorders.

The International journal of neuroscience, 30(4), 277-82

View on PubMed ↗

Citation

Consroe, P; Sandyk, R; Snider, S R. (1986). Open label evaluation of cannabidiol in dystonic movement disorders.. The International journal of neuroscience, 30(4), 277-82.